therapies continue will This on the call to live thank Melissa. everyone and better two who's which strategy you us six to Entinostat webcast. corporate And the Slide afternoon our the summarizes our third of made execute cancer develop progress X our longer potential enable support are much, you we've I'll as that joining patients on today's pipeline corporate and during Great, briefly is before. across to we ever very mission best-in-class being indications. includes and primary clinical share which ongoing on thank innovative which than SNDX-XXXX trials in tested molecules; different and five with quarter
of assets trial. progress a highlight in we provides payment a to Phase previously more this of update Vitae to call. share ENCORE This in-depth small quarter of through exemestane monotherapy Phase update milestone milestone. combination with trial our versus Menin which we've all you. X an Japanese that with recurrent trial entinostat study MLL-r with again randomized in KHK X on Allergan Kyowa is ongoing like a hormone I'm is license receptor these Kirin Syndax placebo-controlled, the to about for a to milestones Pharmaceuticals, patient Phase of set X Hakko a X agreement also subsidiary and molecule entinostat expanded that I'll later negative third I'd running or testing pivotal million breast first Slide of positive in communicated double-blind, patients interaction. of our the pipeline dosed see advanced the of an pleased Slide HERX steady inhibitors pivotal X cancer. the assets Kirin. $X the triggered XXX exemestane EXXXX these from recently to to Similar portfolio
concept These with we've presented year earlier were findings entinostat refractory reinforce released cancer adding responses non-small in results cell the the ASCO in in seen saw since lung treated our we abstract combination. this that PD-X PD-X some cohort refractory you melanoma that the the this at reserve cell patients it's As morning of and PD-X cohort received from interesting KEYTRUDA as support can the has led target cancer to to second reached investigators lung data XX a of been rapid that our resistance total data entinostat patients. additional the by to non-small its is therapies. well of enrolling accrual now This stage which
trial inhibitors. the least into the met morning. As The threshold the who we in patients. the advance second patients Phase abstracts We've non-small also responses four to noted lung stage was there is enrolling cell cancer goal to we've objective at have previously received cohort response X in PD-LX this for pre-specified the of which release not XX
this at this However, stage cohort we've not progress this to data promising second time. chosen of despite the extremely to
As X trial each cohort naïve the XXX target and the safety of two enrolment those pleased Leena made designed. non-small the the current five trials you before cohort PD-LX and cancer. trials cell like the cell of both enrolment. stages and near first The covering as efficacy patients stage from refractory which pivotal to for colorectal stage out of cancer from I'm non-small of enrolment term Encore delivered provides non-small Encore the in Stage who've trials the status first at in cell many cell remarkable cohort. the non-small some lung of in the Gandhi XX both summary reading patients. population the cancer oral over of line that cohort the lung patients full this progress We see refractory lung in know there the enrolment in Slide SITC are undertake data and to lung the from Saturday cancer. this of NYU second further This cohort with and the report X cohorts XXX XX data achieving at we quarter presentation all
with lung at X that least Stage we've the with previously met for four who've to advance note antagonist patients responses. PD-X of again treated cell cohort You'll threshold been not non-small cancer to with the
patients refractory update refractory from first full cohort, half The As all clinical patients. colorectal cancer the first lung XX XXXX. previously non-small the can expect you in patients XX full communicated, cohort on the cell cohort the melanoma XX data the of the and
make Let few patients XXX melanoma options of Encore or PD-X treatment about comments data at upon development presented patients FDA for alone and We patients combination clinical this ASCO unmet based of providing with new melanoma Slide indication from CTLA-X updated cohort the anticipate the this plans unmet this series our inhibitor. that high fail the a antagonist refractory year me undertook for for both either of consultations with need XXX. refractory clearly medical area update XXXX in melanoma XX of we from highlights the a who program. the on trial promising registration with and X need half an in clinical of our European on It's Encore the population now full and and the agency. of refractory we with first with data regulatory along an
of of This results triple to who Turning remains review in XXXX. combination our have two Roche Encore Slide with X, TECENTRIQ expect to of I'll complete antibody Phase now which of women systemic remain with of negative and in enrolment in of entinostat portion second the have on PD-LX to briefly Xb/X the the XXX remainder in breast of Genentech's first is XXXX for track ongoing status just program, cancer trial metastatic trial. anti Phase the the or exploring X the received enrolment one lines We therapy. half half randomized the prior the
by and received antibody combination who've half in XXXX the Encore developed five complete BAVENCIO, and Both we Phase first entinostat overall previously testing lines present response For the remains Pfizer-Merck rate with results the our expect for women secondary to cancer in a include three and X in Phase is primary the survival. therapy with endpoint of of advanced which of endpoint similarly first these the XXX ongoing previously anti-PD-LX Xb/X of trial enrolment the as half KGaA progression-free alliance overall shared, is trial the studies XXXX. portion to enrolment ovarian in survival
and will in summarizes an the be analysis trial. that committee this statistician completed held provide Data now data the are analysis the sponsor completion analysis the the ECOG-ACRIN me endpoints. analysis. regarding confidentially until communication the OS interim on XXXX. and study breast enrolment cancer the of from this a first recently will research No release half The and which safety PFS occur design monitor We've X result trial of trial Safety cancer has the Phase group expects of Let Monitoring Committee. our ECOG-ACRIN ECOG-ACRIN first final learned Slide EXXXX X the update
anticipate in The of XX% represents Phase of As the of agents is belief you setting mechanism positive. a may one CKDX/X. second third involving we anticipate We this X completion. novel enrolled PFS and continue trials to trial EXXXX trial action next the that approval important since recall for therapy targets hormone as blockbuster are therapy failing bring if that is to NDA after XX,XXX approximately to or patients potential ECOG our year, entinostat analysis as who breast receive XX could least the severe the on therefore a negative on hormone we see inhibitor. previously you'll belong have positive first XX% that metastatic who Based there patients receptor line and therapy in cancer entinostat. HERX of potentially we be feedback estimate Slide line enrolled received to at will eligible from CDKX/X EXXXX ECOG-ACRIN to with work has to potential filing It's also first receive
IL-XX SNDX-XXXX to in our high other synergistic receptor class prevent targeting profile receptor as a noted includes and and ability monoclonal that turn potential CSF-X of to potential both unique SNDX-XXXX me best to Let classes. we've affinity demonstrated has now CSF-X activity antibody previously therapeutic with binding CSF-X and binding
Ligand tumor based proliferation, combinations As critically with the the a cells which in treatment the immunosuppressive consistent effective therapy. overcome the tumor lymphocytes quarter complementary tumor- in it tumor protein in ascending this during the and differentiation that present with multiple plays in radiation CSF-X, to cell functions of ascending Phase critical checkpoint receptor initiated the found necessitate synergistic this microenvironment week, May infiltrating shown inhibit and tumor agent has cancers surface cohort single also other trial completed to-date, changes to we tumor that cells drug on intense trial more think that suppressor evidence tumors all solid attack that the a inhibitors, blocking role two to microenvironment been used which This X believe the when SNDX-XXXX kill We've CSF-XR. in also additionally And noted with IL-XX variety first in myeloid-derived levels immunosuppressant with we cells will completed immunosuppression the the either dose detailed synergistic cells. the XX, activity novel chemotherapy of the in can CSF-XR regulating microenvironment. the therapies, volunteers of regulatory entinostat T of or with ability domains SITC cell. by dose past of mechanism or for healthy inhibit and the from on cell be Slide at results potential survival We and this shown various has we've monocyte of enrolment circulating study inhibitor. and of later trial. We'll this patients binding we
Turning for potential to Allergan compounds subset chromosomal with XX, application of the recently of Slide acute of exclusive the small have mentioned leukemia agreement defined oral entered we in genetically earlier These into rearrangements the treatment with I inhibitors protein. interaction of MLL-rg. pre-clinical as with our of an Menin the portfolio molecule and worldwide MLL license
generally and disease designation. particular represents need. first of guidelines for as me orphan the that Let well-defined the to meet the as represents area leukemia a either prognosis AML biology, a Might ALL unmet high you also bad MLL-r or introduce
binds also protein thus Slide proteins The Menin. all patient the the of gene, fusion genes. by the There's a see thereby leukemia to routinely family causing a population that MLL-X large protein protein on Menin terminal the the XX, carboxyl to a specific But different this the fusion the MLL abnormal consists panel rate, of portion practice brings right. on diagram of binds a in that on retain of is abnormally is diagram links a immunoterminal DNA family a protein in you'll more fusion this transformation. and fully Menin today. proteins the top causing region to thereby identified transcriptional region activation Importantly of clinical family to including of of The depicted abnormally fusion driven of
genetic genetic to that fusion You We Menin that panel attractive believe protein in the the This specific the binding trials summarized patient a run very in could protein. entire recruited more inhibitors protein and proteins us in sub-population MLL both the block companies we've rapid can for clinical seen are Slide fusion have leads see of allow targeting an involving a potentially prospectively in strategy hence it bottom to displaced. other This afford is decreases developed us of with apoptosis. abnormally harboring focused specific in induction as this as fusion forward the improvement of path of and self-proliferation XX differentiation a as opportunity therapies family defined potentially marker. who an turn targeting regulatory
of right, this This a the number how in-licensing examples potential Syndax through represents another we summarize creates of On transaction example assets. value approach. of high
agreement well sales. As and summarized on may beyond therapeutic of transaction $X sales the develop positioned the downstream involved responsible development, manufacturing leukemia. MLL-r with in development, this future believe diseases and milestones product for the portfolio payment the which tiered global royalties and portfolio contingent of we're and potential Slide unique this a upfront XX, have million to and of commercialization regulatory we're modest we terms Under
to Officer Chief turn the balance on Shea, I Before call sheet. discuss financial to and Rick update our our results over our Financial you
Let This cancer analysis over results in the X includes cohorts me biomarker presentations from the update. SITC of healthy Stage this non-small our to that, refractory initial cohort at remind later data of cell ascending SNDX-XXXX single from Rick of both of as Slide with I'll Encore and week just monotherapy financial the dose as And it the turn volunteers. XXX study on lung results melanoma shown for well Phase XX. X of
